|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of ABCB1 mRNA; Camptothecin results in decreased expression of ABCB1 protein Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA] |
CTD |
PMID:10692111 PMID:29356861 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
decreases response to substance multiple interactions |
ISO |
ABCC1 protein results in decreased susceptibility to Camptothecin analog Camptothecin inhibits the reaction [ABCC1 results in decreased susceptibility to Daunorubicin] |
CTD |
PMID:11778547 PMID:12115804 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Acvr1b |
activin A receptor, type 1B |
increases methylation |
ISO |
Camptothecin results in increased methylation of ACVR1B gene |
CTD |
PMID:30720231 |
|
NCBI chr15:101,071,953...101,111,565
Ensembl chr15:101,071,948...101,111,565
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases response to substance |
ISO |
ADAM19 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr11:45,945,329...46,038,174
Ensembl chr11:45,946,819...46,038,170
|
|
G |
Agap1 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 |
increases methylation |
ISO |
Camptothecin results in increased methylation of AGAP1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 1:89,382,533...89,823,004
Ensembl chr 1:89,382,528...89,825,339
|
|
G |
Agrn |
agrin |
increases expression |
ISO |
Camptothecin results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:156,249,747...156,281,997
Ensembl chr 4:156,249,747...156,281,945
|
|
G |
Agrp |
agouti related neuropeptide |
decreases response to substance |
ISO |
AGRP mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 8:106,293,327...106,306,477
Ensembl chr 8:106,293,330...106,364,025
|
|
G |
Aifm3 |
apoptosis-inducing factor, mitochondrion-associated 3 |
decreases response to substance |
ISO |
AIFM3 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr16:17,307,418...17,325,349
Ensembl chr16:17,307,475...17,325,349
|
|
G |
Akap13 |
A kinase anchor protein 13 |
decreases response to substance |
ISO |
AKAP13 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:75,105,271...75,404,357
Ensembl chr 7:75,105,282...75,404,357
|
|
G |
Akap8 |
A kinase anchor protein 8 |
increases expression |
ISO |
Camptothecin results in increased expression of AKAP8 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr17:32,522,646...32,540,212
Ensembl chr17:32,522,646...32,540,212
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
affects phosphorylation multiple interactions increases phosphorylation |
ISO |
Camptothecin affects the phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein]; Camptothecin results in decreased expression of and results in decreased phosphorylation of AKT1 protein; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in decreased phosphorylation of AKT1 protein]; Nicotine affects the reaction [Camptothecin affects the phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24095863 PMID:30851366 PMID:36394428 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Camptothecin analog binds to ALB protein; Camptothecin binds to ALB protein CTSB protein results in increased cleavage of [Camptothecin analog binds to ALB protein] |
CTD |
PMID:10803926 PMID:17378599 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of ALMS1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 6:85,564,482...85,698,973
Ensembl chr 6:85,564,513...85,679,735
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Camptothecin results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566
|
|
G |
Apc |
APC, WNT signaling pathway regulator |
increases methylation |
ISO |
Camptothecin results in increased methylation of APC gene |
CTD |
PMID:30720231 |
|
NCBI chr18:34,353,350...34,455,243
Ensembl chr18:34,353,977...34,455,605
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Artn |
artemin |
decreases response to substance |
ISO |
ARTN mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:117,783,105...117,787,993
Ensembl chr 4:117,783,359...117,786,960
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
Glutathione inhibits the reaction [Camptothecin results in increased expression of ATF4 protein]; MYC protein affects the reaction [Camptothecin results in increased expression of ATF4 protein] |
CTD |
PMID:30266318 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 mutant form inhibits the reaction [Camptothecin results in increased degradation of SQSTM1 protein] |
CTD |
PMID:22927544 |
|
NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions increases expression |
ISO |
Egtazic Acid inhibits the reaction [Camptothecin results in increased expression of ATG7 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of ATG7 protein]; staurosporine aglycone inhibits the reaction [Camptothecin results in increased expression of ATG7 protein] |
CTD |
PMID:30266318 |
|
NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575
|
|
G |
Atm |
ataxia telangiectasia mutated |
decreases expression increases expression multiple interactions increases activity |
ISO |
Camptothecin results in decreased expression of ATM mRNA Camptothecin results in increased expression of ATM protein modified form Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]] camptothecin increases kinase activity in rat cerebellar granule neurons |
CTD RGD |
PMID:24792648 PMID:30720231 PMID:19151707 |
RGD:10053571 |
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Atr |
ataxia telangiectasia and Rad3 related |
decreases response to substance multiple interactions increases phosphorylation |
ISO |
ATR mRNA results in decreased susceptibility to Camptothecin; ATR protein results in decreased susceptibility to Camptothecin 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased phosphorylation of ATR protein] |
CTD |
PMID:25269479 PMID:30555576 |
|
NCBI chr 9:95,739,655...95,834,813
Ensembl chr 9:95,739,650...95,833,834
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of BAK1 mRNA Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BAK1 mRNA] |
CTD |
PMID:30581319 |
|
NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions increases activity increases expression decreases expression |
ISO |
[Camptothecin co-treated with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] results in decreased expression of BAX protein; Camptothecin affects the cleavage of and results in decreased expression of BAX protein; Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BAX mRNA] Camptothecin results in increased activity of BAX protein Camptothecin results in increased expression of BAX protein pifithrin inhibits the reaction [Camptothecin results in increased expression of BAX protein] Camptothecin results in decreased expression of BAX mRNA; Camptothecin results in decreased expression of BAX protein |
CTD |
PMID:11279278 PMID:15665116 PMID:17555331 PMID:19481069 PMID:30581319 PMID:30885713 More...
|
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
affects response to substance |
EXP |
BBC3 protein affects the susceptibility to Camptothecin |
CTD |
PMID:20477944 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases response to substance decreases expression increases expression |
ISO EXP |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in decreased expression of BCL2 protein]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in decreased expression of BCL2 protein]; Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BCL2 mRNA] BCL2 results in decreased susceptibility to Camptothecin Camptothecin results in decreased expression of BCL2 mRNA; Camptothecin results in decreased expression of BCL2 protein Camptothecin results in increased expression of BCL2 mRNA Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein] |
CTD |
PMID:9664115 PMID:10692111 PMID:10896673 PMID:19481069 PMID:24726431 PMID:25449198 PMID:30581319 PMID:36394428 More...
|
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases response to substance decreases expression increases expression multiple interactions |
ISO |
BCL2L1 gene mutant form results in decreased susceptibility to Camptothecin Camptothecin results in decreased expression of BCL2L1 protein alternative form Camptothecin results in increased expression of BCL2L1 protein Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]; Mifepristone affects the reaction [Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]]; Naphthoquinones analog promotes the reaction [Camptothecin results in increased expression of BCL2L1 protein] BCL2L1 mRNA results in decreased susceptibility to Camptothecin Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 mRNA] |
CTD |
PMID:10970895 PMID:19339209 PMID:19497415 PMID:25269479 PMID:30581319 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Becn1 |
beclin 1, autophagy related |
increases expression multiple interactions |
ISO |
Camptothecin results in increased expression of BECN1 protein [Diethylhexyl Phthalate co-treated with Camptothecin] results in decreased expression of BECN1 protein; Egtazic Acid inhibits the reaction [Camptothecin results in increased expression of BECN1 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of BECN1 protein]; staurosporine aglycone inhibits the reaction [Camptothecin results in increased expression of BECN1 protein] |
CTD |
PMID:30266318 PMID:36394428 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Camptothecin co-treated with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] results in increased cleavage of and results in decreased expression of BID protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of BID protein; Camptothecin results in increased cleavage of and results in decreased expression of BID protein |
CTD |
PMID:19481069 PMID:19633536 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Butyrates co-treated with Camptothecin] results in decreased expression of BIRC5 protein; [Folic Acid co-treated with Camptothecin] results in decreased expression of BIRC5 mRNA Camptothecin results in increased expression of BIRC5 mRNA Camptothecin results in decreased expression of BIRC5 mRNA Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein] |
CTD |
PMID:16061681 PMID:24726431 PMID:25449198 PMID:30581319 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bnip1 |
BCL2/adenovirus E1B interacting protein 1 |
increases expression |
ISO |
Camptothecin results in increased expression of BNIP1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr17:26,999,876...27,011,539
Ensembl chr17:27,000,040...27,011,539
|
|
G |
Brca1 |
breast cancer 1, early onset |
decreases expression decreases response to substance |
ISO |
Camptothecin results in decreased expression of BRCA1 mRNA BRCA1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:10344722 PMID:25269479 |
|
NCBI chr11:101,379,587...101,442,808
Ensembl chr11:101,379,590...101,442,781
|
|
G |
Brca2 |
breast cancer 2, early onset |
decreases expression |
ISO |
Camptothecin results in decreased expression of BRCA2 mRNA |
CTD |
PMID:10344722 |
|
NCBI chr 5:150,445,759...150,493,612
Ensembl chr 5:150,446,095...150,493,794
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
EXP |
Camptothecin results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr19:8,814,831...8,826,047
Ensembl chr19:8,814,831...8,826,047
|
|
G |
Cab39 |
calcium binding protein 39 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:85,707,796...85,779,298
Ensembl chr 1:85,721,162...85,779,297
|
|
G |
Casp2 |
caspase 2 |
increases splicing increases expression |
ISO |
Camptothecin results in increased splicing of CASP2 mRNA Camptothecin results in increased expression of CASP2 mRNA alternative form |
CTD |
PMID:14757846 |
|
NCBI chr 6:42,241,942...42,259,442
Ensembl chr 6:42,241,919...42,259,442
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage |
ISO EXP |
15-deoxyprostaglandin J2 promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; [Camptothecin co-treated with FAS protein] results in increased activity of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP3 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Camptothecin promotes the reaction [15-deoxyprostaglandin J2 results in increased activity of CASP3 protein]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; SMN1 mRNA affects the reaction [Camptothecin results in increased activity of CASP3 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased activity of CASP3 protein] Cadmium Chloride inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Cadmium inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Dexamethasone inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; Tetrachlorodibenzodioxin promotes the reaction [Camptothecin results in increased cleavage of CASP3 protein] |
CTD |
PMID:10896673 PMID:15862279 PMID:15958570 PMID:16263807 PMID:16273314 PMID:16756956 PMID:16962673 PMID:18506790 PMID:19339209 PMID:19481069 PMID:19497415 PMID:19633536 PMID:21683069 PMID:22302033 PMID:24726431 PMID:24792648 PMID:25412314 PMID:25592883 PMID:25843524 PMID:29384525 PMID:30720231 PMID:33248029 PMID:34635930 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity decreases expression |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased activity of CASP7 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP7 protein] Camptothecin results in decreased expression of CASP7 mRNA |
CTD |
PMID:22302033 PMID:24726431 PMID:30581319 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
multiple interactions affects cleavage increases activity increases expression decreases expression |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Camptothecin results in increased activity of CASP8 protein]; [Camptothecin co-treated with FAS protein] results in increased activity of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Camptothecin results in increased activity of CASP8 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP8 protein] Camptothecin affects the cleavage of CASP8 protein Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP8 protein] Camptothecin results in decreased expression of CASP8 mRNA |
CTD |
PMID:10896673 PMID:15475000 PMID:15958570 PMID:19497415 PMID:19633536 PMID:30581319 PMID:30885713 PMID:34635930 More...
|
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity increases cleavage increases expression decreases expression |
ISO |
[Camptothecin co-treated with FAS protein] results in increased activity of CASP9 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP9 protein; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP9 protein] benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of CASP9 protein]; Cadmium Chloride inhibits the reaction [Camptothecin results in increased activity of CASP9 protein]; Cadmium inhibits the reaction [Camptothecin results in increased activity of CASP9 protein]; Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP9 protein] Camptothecin results in decreased expression of CASP9 mRNA |
CTD |
PMID:10896673 PMID:15958570 PMID:16263807 PMID:19497415 PMID:19633536 PMID:24823293 PMID:30581319 PMID:30885713 PMID:34635930 More...
|
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of CAV1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Folic Acid co-treated with Camptothecin] results in decreased expression of CCNA2 mRNA Camptothecin results in decreased expression of CCNA2 mRNA |
CTD |
PMID:30581319 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression decreases expression |
ISO |
[Butyrates co-treated with Camptothecin] results in decreased expression of CCNB1 protein; CDKN1A protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein] Camptothecin results in decreased expression of CCNB1 protein |
CTD |
PMID:16061681 PMID:23376119 PMID:30851366 PMID:30885713 PMID:31255635 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Ccnd1 |
cyclin D1 |
affects localization |
EXP |
Camptothecin affects the localization of CCND1 protein |
CTD |
PMID:14647467 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
Camptothecin results in increased expression of CCNE1 protein |
CTD |
PMID:30851366 |
|
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
Camptothecin promotes the reaction [MAD2L1 protein binds to CDC20 protein] |
CTD |
PMID:30885713 |
|
NCBI chr 4:118,290,098...118,294,540
Ensembl chr 4:118,290,098...118,294,549
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
multiple interactions |
ISO |
Camptothecin results in increased expression of and results in increased activity of CDK1 protein; CDKN1A protein affects the reaction [Camptothecin results in increased activity of CDK1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of and results in increased activity of CDK1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CDK1 protein] |
CTD |
PMID:30885713 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases activity |
ISO |
Camptothecin results in increased phosphorylation of and results in decreased activity of CDK2 protein camptothecin increases kinase activity in rat cerebellar granule neurons |
CTD RGD |
PMID:15141020 PMID:19151707 |
RGD:10053571 |
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdk5 |
cyclin dependent kinase 5 |
increases activity |
ISO |
camptothecin increases kinase activity in rat cerebellar granule neurons |
RGD |
PMID:19151707 |
RGD:10053571 |
NCBI chr 5:24,612,595...24,628,737
Ensembl chr 5:24,623,239...24,628,528
|
|
G |
Cdk5r1 |
cyclin dependent kinase 5, regulatory subunit 1 |
increases expression |
ISO |
Camptothecin results in increased expression of CDK5R1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:80,367,849...80,372,010
Ensembl chr11:80,367,849...80,372,010
|
|
G |
Cdk6 |
cyclin dependent kinase 6 |
increases activity |
ISO |
camptothecin increases kinase activity in rat cerebellar granule neurons |
RGD |
PMID:19151707 |
RGD:10053571 |
NCBI chr 5:3,391,004...3,581,008
Ensembl chr 5:3,391,485...3,581,008
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Camptothecin results in increased expression of CDKN1A mRNA; Camptothecin results in increased expression of CDKN1A protein Aspirin inhibits the reaction [Camptothecin results in increased expression of CDKN1A protein]; Camptothecin results in increased expression of and results in increased phosphorylation of CDKN1A protein; CDKN1A protein affects the reaction [Camptothecin results in increased activity of CDK1 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein] |
CTD |
PMID:9673414 PMID:17555331 PMID:19212664 PMID:24211769 PMID:30022047 PMID:30851366 PMID:30885713 More...
|
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Camptothecin results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 7:25,161,127...25,177,072
Ensembl chr 7:25,161,132...25,177,028
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
Camptothecin results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:79,226,432...79,244,499
Ensembl chr17:79,226,435...79,244,495
|
|
G |
Cep85l |
centrosomal protein 85-like |
increases methylation |
ISO |
Camptothecin results in increased methylation of CEP85L gene |
CTD |
PMID:30720231 |
|
NCBI chr10:53,149,537...53,256,765
Ensembl chr10:53,149,539...53,256,043
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
EXP |
Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein] |
CTD |
PMID:25449198 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions increases phosphorylation increases expression decreases response to substance |
EXP ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of CHEK1 mRNA]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein]; Caffeine inhibits the reaction [Camptothecin results in increased expression of CHEK1 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein] 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased expression of CHEK1 protein modified form]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of CHEK1 protein modified form] CHEK1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:21646468 PMID:22403396 PMID:25269479 PMID:30555576 PMID:30720231 |
|
NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression increases phosphorylation multiple interactions |
ISO |
Camptothecin results in increased expression of CHEK2 protein modified form Camptothecin results in increased phosphorylation of CHEK2 protein Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:21646468 PMID:25269479 PMID:25977998 PMID:30720231 |
|
NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011
|
|
G |
Clptm1l |
CLPTM1-like |
increases response to substance |
ISO |
CLPTM1L mutant form results in increased susceptibility to Camptothecin |
CTD |
PMID:22675468 |
|
NCBI chr13:73,752,121...73,768,758
Ensembl chr13:73,752,125...73,768,724
|
|
G |
Coil |
coilin |
increases expression |
ISO |
Camptothecin results in increased expression of COIL mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:88,864,761...88,882,439
Ensembl chr11:88,861,078...88,882,439
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]; Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]]; pifithrin inhibits the reaction [Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]] |
CTD |
PMID:13679428 |
|
NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
|
|
G |
Crx |
cone-rod homeobox |
decreases response to substance |
ISO |
CRX mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:15,599,872...15,613,880
Ensembl chr 7:15,599,872...15,613,893
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
CTSB protein results in increased cleavage of [Camptothecin analog binds to ALB protein] |
CTD |
PMID:17378599 |
|
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
decreases expression increases secretion multiple interactions decreases response to substance |
ISO |
Camptothecin results in decreased expression of CXCL8 protein Camptothecin results in increased secretion of CXCL8 protein Ciprofloxacin inhibits the reaction [Camptothecin results in increased secretion of CXCL8 protein]; moxifloxacin inhibits the reaction [Camptothecin results in increased secretion of CXCL8 protein] CXCL8 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16356833 PMID:18191106 PMID:20116850 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin affects the localization of CYCS protein] |
CTD |
PMID:19481069 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
decreases response to substance |
ISO |
CYP26B1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 6:84,548,396...84,570,890
Ensembl chr 6:84,548,396...84,570,890
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of CYP2B6 mRNA Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
multiple interactions decreases expression |
ISO |
Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA] Camptothecin results in decreased expression of CYP2C8 mRNA |
CTD |
PMID:29356861 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions decreases expression |
ISO |
Camptothecin results in increased expression of DDIT3 protein Folic Acid inhibits the reaction [Camptothecin results in decreased expression of DDIT3 mRNA]; MYC protein affects the reaction [Camptothecin results in increased expression of DDIT3 protein] |
CTD |
PMID:30266318 PMID:30581319 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Dgkz |
diacylglycerol kinase zeta |
decreases response to substance |
ISO |
DGKZ mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 2:91,763,167...91,806,788
Ensembl chr 2:91,763,169...91,806,209
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions decreases expression decreases activity |
ISO |
Camptothecin inhibits the reaction [Fluorouracil results in increased expression of DPYD mRNA] Camptothecin results in decreased expression of DPYD mRNA Camptothecin results in decreased activity of DPYD protein |
CTD |
PMID:16568373 |
|
NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573
|
|
G |
Dtwd1 |
DTW domain containing 1 |
increases expression |
ISO |
Camptothecin results in increased expression of DTWD1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:125,993,981...126,007,197
Ensembl chr 2:125,994,061...126,007,199
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions increases expression |
EXP |
7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]; E2F1 protein promotes the reaction [Camptothecin results in increased expression of RRM2 protein] |
CTD |
PMID:22403396 |
|
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
ISO |
Camptothecin results in increased expression of E2F8 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 7:48,516,177...48,531,821
Ensembl chr 7:48,516,177...48,531,344
|
|
G |
Ei24 |
etoposide induced 2.4 mRNA |
increases expression |
ISO |
Camptothecin results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:36,690,449...36,708,630
Ensembl chr 9:36,690,455...36,708,689
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Camptothecin results in increased phosphorylation of EIF2AK3 protein Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:30266318 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
increases phosphorylation multiple interactions |
ISO |
Camptothecin results in increased phosphorylation of EIF2S1 protein EIF2S1 protein affects the reaction [Camptothecin results in increased expression of ATG7 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of BECN1 protein]; Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein] [Camptothecin co-treated with GW 506033X] results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:19046382 PMID:30266318 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
Camptothecin results in decreased expression of EP300 mRNA; Camptothecin results in decreased expression of EP300 protein |
CTD |
PMID:10344722 |
|
NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
Camptothecin results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:111,100,913...111,108,161
Ensembl chr 9:111,100,997...111,108,161
|
|
G |
Ercc1 |
excision repair cross-complementing rodent repair deficiency, complementation group 1 |
multiple interactions decreases expression |
ISO |
ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] Camptothecin results in decreased expression of ERCC1 mRNA |
CTD |
PMID:21227924 PMID:24792648 |
|
NCBI chr 7:19,079,016...19,090,449
Ensembl chr 7:19,078,703...19,090,449
|
|
G |
Ercc4 |
excision repair cross-complementing rodent repair deficiency, complementation group 4 |
multiple interactions decreases response to substance |
ISO |
ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] ERCC4 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:21227924 |
|
NCBI chr16:12,927,600...12,969,873
Ensembl chr16:12,927,548...12,968,481
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of ESR1 protein; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]] |
CTD |
PMID:25752796 PMID:30720231 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Camptothecin results in increased expression of and affects the localization of FAS protein]; [Camptothecin co-treated with FAS protein] results in decreased expression of XIAP protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP9 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of BID protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP9 protein; Camptothecin results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Camptothecin results in increased expression of and affects the localization of FAS protein] |
CTD |
PMID:15475000 PMID:15958570 PMID:19633536 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
Camptothecin results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr11:115,158,850...115,167,925
Ensembl chr11:115,158,850...115,167,876
|
|
G |
Fxn |
frataxin |
increases expression |
ISO |
Camptothecin results in increased expression of FXN protein |
CTD |
PMID:23418481 |
|
NCBI chr19:24,236,909...24,257,954
Ensembl chr19:24,238,817...24,257,969
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of FZD1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 5:4,803,839...4,808,216
Ensembl chr 5:4,803,839...4,808,035
|
|
G |
Fzd8 |
frizzled class receptor 8 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of FZD8 gene |
CTD |
PMID:30720231 |
|
NCBI chr18:9,212,856...9,216,201
Ensembl chr18:9,212,163...9,218,136
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible 45 alpha |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of GADD45A mRNA Folic Acid inhibits the reaction [Camptothecin results in decreased expression of GADD45A mRNA] |
CTD |
PMID:24792648 PMID:30581319 |
|
NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible 45 gamma |
increases expression |
ISO |
Camptothecin results in increased expression of GADD45G mRNA |
CTD |
PMID:24792648 |
|
NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504
|
|
G |
Git2 |
GIT ArfGAP 2 |
decreases response to substance |
ISO |
GIT2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 5:114,865,469...114,912,647
Ensembl chr 5:114,865,468...114,913,578
|
|
G |
Gm20348 |
predicted gene, 20348 |
increases expression |
ISO |
Camptothecin results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr12:4,860,475...4,867,155
Ensembl chr12:4,860,494...4,867,142
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases response to substance |
ISO |
GPX4 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
increases expression decreases response to substance |
ISO |
Camptothecin results in increased expression of GSTP1 protein GSTP1 protein polymorphism results in decreased susceptibility to Camptothecin; GSTP1 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:14732228 PMID:15500952 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression increases phosphorylation |
ISO EXP |
3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; [Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; [MIR138-1 results in decreased expression of H2AX] which results in increased susceptibility to Camptothecin; [Propyl Gallate results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]]; H2AX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin]; palbociclib inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; PPP2R2A protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; PPP2R5C protein promotes the reaction [Camptothecin results in increased expression of H2AX protein modified form]; PPP2R5E protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein] Camptothecin results in increased expression of H2AX protein; Camptothecin results in increased expression of H2AX protein modified form Camptothecin results in increased phosphorylation of H2AX protein |
CTD |
PMID:17875725 PMID:21227924 PMID:21646468 PMID:21693595 PMID:22302033 PMID:25269479 PMID:25772433 PMID:26928355 PMID:30720231 PMID:32482060 More...
|
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression |
ISO |
Camptothecin results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457
|
|
G |
Hemk1 |
HemK methyltransferase family member 1 |
decreases response to substance |
ISO |
HEMK1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 9:107,204,281...107,217,640
Ensembl chr 9:107,204,283...107,215,549
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
multiple interactions |
ISO |
[HNRNPC protein binds to HNRNPC protein alternative form] which results in decreased susceptibility to Camptothecin |
CTD |
PMID:16960656 |
|
NCBI chr14:52,310,834...52,341,462
Ensembl chr14:52,310,834...52,341,485
|
|
G |
Hoxa1 |
homeobox A1 |
decreases response to substance multiple interactions |
ISO EXP |
HOXA1 mRNA results in decreased susceptibility to Camptothecin Camptothecin inhibits the reaction [Vitamin A results in increased expression of HOXA1] |
CTD |
PMID:25269479 PMID:26820057 |
|
NCBI chr 6:52,132,573...52,135,299
Ensembl chr 6:52,132,570...52,135,297
|
|
G |
Ibsp |
integrin binding sialoprotein |
decreases response to substance |
ISO |
IBSP mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 5:104,447,153...104,459,338
Ensembl chr 5:104,447,037...104,459,335
|
|
G |
Il1b |
interleukin 1 beta |
decreases response to substance |
ISO |
IL1B protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16356833 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6ra |
interleukin 6 receptor, alpha |
decreases expression |
ISO |
Camptothecin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503
|
|
G |
Jarid2 |
jumonji and AT-rich interaction domain containing 2 |
decreases expression |
ISO |
Camptothecin results in decreased expression of JARID2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr13:44,881,817...45,075,119
Ensembl chr13:44,882,950...45,075,119
|
|
G |
Jun |
jun proto-oncogene |
increases expression increases phosphorylation multiple interactions |
ISO |
Camptothecin results in increased expression of JUN protein Camptothecin results in increased phosphorylation of JUN protein Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of JUN protein]; MAPK8 protein affects the reaction [Camptothecin results in increased phosphorylation of JUN protein] |
CTD |
PMID:9751194 PMID:15585644 PMID:30266318 PMID:30885713 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kcnk2 |
potassium channel, subfamily K, member 2 |
decreases response to substance |
ISO |
KCNK2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:188,940,127...189,134,951
Ensembl chr 1:188,940,127...189,134,470
|
|
G |
Klhl42 |
kelch-like 42 |
increases expression |
ISO |
Camptothecin results in increased expression of KLHL42 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:146,990,783...147,014,276
Ensembl chr 6:146,992,877...147,014,276
|
|
G |
Lgals1 |
lectin, galactose binding, soluble 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of LGALS1 mRNA; Camptothecin results in decreased expression of LGALS1 protein |
CTD |
PMID:19483324 |
|
NCBI chr15:78,810,925...78,814,665
Ensembl chr15:78,810,925...78,814,665
|
|
G |
Lrch4 |
leucine-rich repeats and calponin homology (CH) domain containing 4 |
decreases response to substance |
ISO |
LRCH4 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 5:137,627,385...137,639,361
Ensembl chr 5:137,627,383...137,639,361
|
|
G |
Mad2l1 |
MAD2 mitotic arrest deficient-like 1 |
multiple interactions increases expression |
ISO |
Camptothecin promotes the reaction [MAD2L1 protein binds to CDC20 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of and results in increased activity of CDK1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP8 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP9 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein] Camptothecin results in increased expression of MAD2L1 mRNA; Camptothecin results in increased expression of MAD2L1 protein |
CTD |
PMID:30885713 |
|
NCBI chr 6:66,512,205...66,518,091
Ensembl chr 6:66,512,374...66,524,204
|
|
G |
Map2k3 |
mitogen-activated protein kinase kinase 3 |
increases expression |
ISO |
Camptothecin results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr11:60,822,880...60,843,637
Ensembl chr11:60,822,859...60,843,637
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Camptothecin results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:19,809,847...20,018,496
Ensembl chr10:19,810,218...20,018,499
|
|
G |
Map3k7 |
mitogen-activated protein kinase kinase kinase 7 |
decreases response to substance |
ISO |
MAP3K7 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
[Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:24095863 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
[Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:24095863 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
Camptothecin results in increased phosphorylation of MAPK8 protein MAPK8 protein affects the reaction [Camptothecin results in increased activity of SP1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CDK1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased phosphorylation of JUN protein] |
CTD |
PMID:30885713 PMID:31255635 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
ISO |
Camptothecin results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:15585644 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Camptothecin results in decreased expression of MAPT mRNA; Camptothecin results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
multiple interactions |
ISO |
[Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; [Propyl Gallate results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; Aminacrine inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; Camptothecin results in increased activity of and affects the localization of MDC1 protein; Propyl Gallate inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein] |
CTD |
PMID:26928355 |
|
NCBI chr17:36,152,390...36,170,562
Ensembl chr17:36,152,407...36,170,562
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
increases expression |
ISO |
Camptothecin results in increased expression of MDM2 protein |
CTD |
PMID:17555331 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression |
ISO |
Camptothecin results in decreased expression of MGMT mRNA |
CTD |
PMID:18492797 |
|
NCBI chr 7:136,496,315...136,732,001
Ensembl chr 7:136,496,343...136,731,995
|
|
G |
Mir138-1 |
microRNA 138-1 |
multiple interactions increases response to substance |
ISO |
[MIR138-1 results in decreased expression of H2AX] which results in increased susceptibility to Camptothecin; H2AX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin] |
CTD |
PMID:21693595 |
|
NCBI chr 9:122,511,941...122,512,039
Ensembl chr 9:122,511,941...122,512,039
|
|
G |
Mir145a |
microRNA 145a |
increases expression decreases expression |
ISO |
Camptothecin results in increased expression of MIR145 mRNA Camptothecin results in decreased expression of MIR145 mRNA |
CTD |
PMID:24726431 |
|
NCBI chr18:61,780,896...61,780,965
Ensembl chr18:61,780,896...61,780,965
|
|
G |
Mir15a |
microRNA 15a |
increases expression decreases expression |
ISO |
Camptothecin results in increased expression of MIR15A mRNA Camptothecin results in decreased expression of MIR15A mRNA |
CTD |
PMID:24726431 |
|
NCBI chr14:61,869,476...61,869,559
Ensembl chr14:61,869,476...61,869,559
|
|
G |
Mir34a |
microRNA 34a |
increases expression |
ISO |
Camptothecin results in increased expression of MIR34A mRNA |
CTD |
PMID:24726431 |
|
NCBI chr 4:150,152,911...150,153,012
Ensembl chr 4:150,152,911...150,153,012
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases response to substance decreases methylation |
ISO |
MMP9 mRNA results in decreased susceptibility to Camptothecin Camptothecin results in decreased methylation of MMP9 gene |
CTD |
PMID:25269479 PMID:30720231 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mre11a |
MRE11A homolog A, double strand break repair nuclease |
decreases expression |
ISO |
Camptothecin results in decreased expression of MRE11 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr 9:14,695,971...14,748,421
Ensembl chr 9:14,695,950...14,748,419
|
|
G |
Mtmr2 |
myotubularin related protein 2 |
decreases response to substance |
ISO |
MTMR2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 9:13,660,397...13,720,192
Ensembl chr 9:13,659,706...13,717,777
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
Camptothecin results in decreased expression of MTOR protein |
CTD |
PMID:31255635 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Myc |
myelocytomatosis oncogene |
increases expression affects localization multiple interactions |
ISO |
Camptothecin results in increased expression of MYC mRNA Camptothecin affects the localization of MYC protein Camptothecin results in increased expression of and results in increased activity of MYC protein; MYC protein affects the reaction [Camptothecin results in increased expression of ATF4 protein]; MYC protein affects the reaction [Camptothecin results in increased expression of DDIT3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein]; TERT protein affects the reaction [Camptothecin results in increased expression of MYC protein] |
CTD |
PMID:30266318 PMID:30851366 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Myo1e |
myosin IE |
decreases expression |
ISO |
Camptothecin results in decreased expression of MYO1E mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 9:70,114,632...70,307,349
Ensembl chr 9:70,114,632...70,307,048
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases response to substance |
ISO |
NCAM1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 9:49,413,434...49,710,909
Ensembl chr 9:49,413,436...49,710,225
|
|
G |
Nck2 |
non-catalytic region of tyrosine kinase adaptor protein 2 |
decreases expression |
ISO |
Camptothecin results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:43,484,643...43,609,678
Ensembl chr 1:43,483,739...43,609,675
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]] |
CTD |
PMID:29356861 |
|
NCBI chr12:4,297,362...4,569,452
Ensembl chr12:4,297,362...4,527,182
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [NCOR2 protein binds to NR1I2 protein] |
CTD |
PMID:29356861 |
|
NCBI chr 5:125,094,217...125,256,302
Ensembl chr 5:125,094,217...125,256,283
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
increases activity multiple interactions |
ISO |
Camptothecin results in increased activity of NFE2L2 protein NFE2L2 protein affects the reaction [Camptothecin results in increased expression of TERT mRNA] |
CTD |
PMID:30851366 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] |
CTD |
PMID:29356861 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Or7c70 |
olfactory receptor family 7 subfamily C member 70 |
decreases response to substance |
ISO |
OR7C2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr10:78,682,785...78,683,747
Ensembl chr10:78,680,886...78,688,000
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions increases cleavage affects response to substance decreases response to substance |
ISO EXP |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; Camptothecin results in increased ADP-ribosylation of and results in increased degradation of PARP1 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Camptothecin results in increased ADP-ribosylation of and results in increased degradation of PARP1 protein]; Nicotine inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; PARP1 protein promotes the reaction [Camptothecin results in increased abundance of Poly Adenosine Diphosphate Ribose]; RBL2 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; XRCC1 protein affects the reaction [PARP1 protein affects the susceptibility to Camptothecin] [Camptothecin co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; [veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin Tetrachlorodibenzodioxin promotes the reaction [Camptothecin results in increased cleavage of PARP1 protein] PARP1 results in decreased susceptibility to Camptothecin |
CTD |
PMID:11741290 PMID:15585644 PMID:16962673 PMID:18506790 PMID:19559722 PMID:22158865 PMID:23376119 PMID:24095863 PMID:24726431 PMID:24792648 PMID:24823293 PMID:25412314 PMID:25449198 PMID:25843524 PMID:27694308 PMID:29384525 PMID:31255635 PMID:35778544 More...
|
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Plk3 |
polo like kinase 3 |
increases expression |
ISO |
Camptothecin results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:116,985,852...116,991,244
Ensembl chr 4:116,985,852...116,991,160
|
|
G |
Ppp1r16b |
protein phosphatase 1, regulatory subunit 16B |
decreases response to substance |
ISO |
PPP1R16B mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 2:158,508,653...158,608,254
Ensembl chr 2:158,507,318...158,608,254
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory inhibitor subunit 1B |
decreases response to substance |
ISO |
PPP1R1B protein alternative form results in decreased susceptibility to Camptothecin; PPP1R1B protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16061638 |
|
NCBI chr11:98,239,232...98,248,622
Ensembl chr11:98,239,230...98,248,622
|
|
G |
Ppp2ca |
protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform |
multiple interactions |
ISO |
Camptothecin affects the localization of [PPP2R5E protein binds to PPP2CA protein] |
CTD |
PMID:25772433 |
|
NCBI chr11:51,989,651...52,013,576
Ensembl chr11:51,989,508...52,018,605
|
|
G |
Ppp2r1a |
protein phosphatase 2, regulatory subunit A, alpha |
affects localization decreases response to substance |
ISO |
Camptothecin affects the localization of PPP2R1A protein PPP2R1A mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 PMID:25772433 |
|
NCBI chr17:21,165,716...21,186,167
Ensembl chr17:21,165,573...21,186,178
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
multiple interactions decreases response to substance |
ISO |
PPP2R2A protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R2A protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr14:67,251,505...67,309,920
Ensembl chr14:67,251,505...67,309,893
|
|
G |
Ppp2r5c |
protein phosphatase 2, regulatory subunit B', gamma |
multiple interactions increases response to substance |
ISO |
PPP2R5C protein promotes the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R5C protein results in increased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr12:110,413,532...110,549,509
Ensembl chr12:110,413,554...110,549,496
|
|
G |
Ppp2r5e |
protein phosphatase 2, regulatory subunit B', epsilon |
multiple interactions decreases response to substance |
ISO |
Camptothecin affects the localization of [PPP2R5E protein binds to PPP2CA protein]; PPP2R5E protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R5E protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr12:75,496,237...75,643,064
Ensembl chr12:75,497,655...75,643,019
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 7:79,944,224...79,966,007
Ensembl chr 7:79,944,198...79,966,007
|
|
G |
Psd3 |
pleckstrin and Sec7 domain containing 3 |
decreases expression |
ISO |
Camptothecin results in decreased expression of PSD3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 8:68,141,728...68,664,740
Ensembl chr 8:68,141,734...68,664,679
|
|
G |
Ptar1 |
protein prenyltransferase alpha subunit repeat containing 1 |
decreases response to substance |
ISO |
PTAR1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr19:23,664,728...23,710,249
Ensembl chr19:23,664,793...23,709,032
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Camptothecin results in decreased expression of and results in decreased phosphorylation of PTEN protein |
CTD |
PMID:30885713 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptpro |
protein tyrosine phosphatase receptor type O |
decreases response to substance |
ISO |
PTPRO mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 6:137,229,189...137,440,251
Ensembl chr 6:137,229,317...137,440,231
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
ISO |
Camptothecin results in decreased expression of RAD50 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr11:53,540,346...53,598,146
Ensembl chr11:53,540,346...53,598,146
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
ISO |
Camptothecin results in decreased expression of RAD51 mRNA; Camptothecin results in decreased expression of RAD51 protein |
CTD |
PMID:10344722 PMID:24792648 |
|
NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926
|
|
G |
Rad51c |
RAD51 paralog C |
increases response to substance |
ISO |
RAD51C gene mutant form results in increased susceptibility to Camptothecin |
CTD |
PMID:20400963 |
|
NCBI chr11:87,267,471...87,295,780
Ensembl chr11:87,267,471...87,295,780
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases methylation |
ISO |
Camptothecin results in increased methylation of RARA gene |
CTD |
PMID:30720231 |
|
NCBI chr11:98,818,626...98,865,768
Ensembl chr11:98,818,644...98,865,768
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation affects response to substance |
ISO EXP |
Camptothecin results in increased phosphorylation of RB1 protein RB1 protein affects the susceptibility to Camptothecin |
CTD |
PMID:14647467 PMID:14704340 PMID:15064736 PMID:15585644 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of RBL1 protein |
CTD |
PMID:15585644 |
|
NCBI chr 2:156,987,813...157,046,454
Ensembl chr 2:156,987,813...157,046,454
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
multiple interactions decreases response to substance |
ISO |
RBL2 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] RBL2 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:15585644 |
|
NCBI chr 8:91,796,685...91,850,472
Ensembl chr 8:91,796,685...91,850,472
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
increases response to substance multiple interactions |
ISO EXP |
RELA results in increased susceptibility to Camptothecin Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]] Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein] Camptothecin results in increased expression of and results in decreased phosphorylation of RELA protein; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in decreased phosphorylation of RELA protein]; Diethylhexyl Phthalate promotes the reaction [Camptothecin results in increased expression of RELA protein] |
CTD |
PMID:13679428 PMID:21737676 PMID:25449198 PMID:36394428 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
ISO |
Camptothecin results in decreased expression of RET protein |
CTD |
PMID:17555550 |
|
NCBI chr 6:118,128,709...118,174,705
Ensembl chr 6:118,128,706...118,174,679
|
|
G |
Rnf31 |
ring finger protein 31 |
decreases response to substance |
ISO |
RNF31 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr14:55,829,199...55,841,131
Ensembl chr14:55,829,165...55,841,150
|
|
G |
Rps6 |
ribosomal protein S6 |
increases expression |
EXP |
Camptothecin results in increased expression of RPS6 protein modified form |
CTD |
PMID:29384525 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Rrm2 |
ribonucleotide reductase M2 |
multiple interactions increases expression |
EXP |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of RRM2 mRNA]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; Caffeine inhibits the reaction [Camptothecin results in increased expression of RRM2 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; E2F1 protein promotes the reaction [Camptothecin results in increased expression of RRM2 protein] Camptothecin results in increased expression of RRM2 mRNA; Camptothecin results in increased expression of RRM2 protein |
CTD |
PMID:22403396 |
|
NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145
|
|
G |
Rwdd3 |
RWD domain containing 3 |
increases expression |
ISO |
Camptothecin results in increased expression of RWDD3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:120,949,046...120,965,427
Ensembl chr 3:120,949,047...120,965,344
|
|
G |
Sdc1 |
syndecan 1 |
increases expression |
ISO |
Camptothecin results in increased expression of SDC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr12:8,821,396...8,843,716
Ensembl chr12:8,821,323...8,843,715
|
|
G |
Sel1l |
sel-1 suppressor of lin-12-like (C. elegans) |
decreases response to substance |
ISO |
SEL1L mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr12:91,772,817...91,815,931
Ensembl chr12:91,772,817...91,815,931
|
|
G |
Sgtb |
small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta |
decreases expression |
ISO |
Camptothecin results in decreased expression of SGTB mRNA |
CTD |
PMID:33770205 |
|
NCBI chr13:104,246,233...104,278,369
Ensembl chr13:104,246,249...104,278,243
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
[SIRT1 mutant form co-treated with Camptothecin] results in increased acetylation of TP53 protein; Camptothecin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased expression of SIRT1 protein] Camptothecin results in decreased expression of SIRT1 protein |
CTD |
PMID:24726431 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc2a12 |
solute carrier family 2 (facilitated glucose transporter), member 12 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SLC2A12 gene |
CTD |
PMID:30720231 |
|
NCBI chr10:22,488,821...22,579,779
Ensembl chr10:22,520,910...22,580,184
|
|
G |
Smn1 |
survival motor neuron 1 |
multiple interactions increases response to substance |
ISO |
SMN1 mRNA affects the reaction [Camptothecin results in increased activity of CASP3 protein] SMN1 protein results in increased susceptibility to Camptothecin |
CTD |
PMID:15862279 |
|
NCBI chr13:100,259,713...100,274,206
Ensembl chr13:100,261,360...100,274,198
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3, neutral |
increases expression |
ISO |
Camptothecin results in increased expression of SMPD3 mRNA |
CTD |
PMID:19698806 |
|
NCBI chr 8:106,979,180...107,064,597
Ensembl chr 8:106,979,180...107,064,620
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions increases expression |
ISO |
Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of SOD1 protein] |
CTD |
PMID:30720231 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions increases expression |
ISO |
Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of SOD2 protein] |
CTD |
PMID:30720231 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sox11 |
SRY (sex determining region Y)-box 11 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX11 gene |
CTD |
PMID:30720231 |
|
NCBI chr12:27,384,267...27,392,717
Ensembl chr12:27,384,263...27,392,573
|
|
G |
Sox12 |
SRY (sex determining region Y)-box 12 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX12 gene |
CTD |
PMID:30720231 |
|
NCBI chr 2:152,235,531...152,239,966
Ensembl chr 2:152,235,531...152,239,983
|
|
G |
Sox17 |
SRY (sex determining region Y)-box 17 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX17 gene |
CTD |
PMID:30720231 |
|
NCBI chr 1:4,561,154...4,567,624
Ensembl chr 1:4,561,154...4,567,577
|
|
G |
Sox3 |
SRY (sex determining region Y)-box 3 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX3 gene |
CTD |
PMID:30720231 |
|
NCBI chr X:59,934,972...59,937,045
Ensembl chr X:59,934,972...59,937,036
|
|
G |
Sox4 |
SRY (sex determining region Y)-box 4 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX4 gene |
CTD |
PMID:30720231 |
|
NCBI chr13:29,132,902...29,137,682
Ensembl chr13:29,132,902...29,137,696
|
|
G |
Sox8 |
SRY (sex determining region Y)-box 8 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX8 gene |
CTD |
PMID:30720231 |
|
NCBI chr17:25,784,865...25,789,666
Ensembl chr17:25,784,634...25,789,726
|
|
G |
Sp1 |
trans-acting transcription factor 1 |
multiple interactions increases activity increases expression |
ISO |
Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of SP1 mRNA]; Camptothecin results in increased activity of and affects the localization of SP1 protein; Camptothecin results in increased expression of and results in increased activity of SP1 protein; MAPK8 protein affects the reaction [Camptothecin results in increased activity of SP1 protein]; mithramycin A inhibits the reaction [Camptothecin results in increased activity of SP1 protein]; TERT protein affects the reaction [Camptothecin results in increased expression of SP1 protein] |
CTD |
PMID:11261509 PMID:30851366 PMID:30885713 |
|
NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839
|
|
G |
Sp3 |
trans-acting transcription factor 3 |
increases activity multiple interactions |
ISO |
Camptothecin results in increased activity of SP3 protein mithramycin A inhibits the reaction [Camptothecin results in increased activity of SP3 protein] |
CTD |
PMID:11261509 |
|
NCBI chr 2:72,766,774...72,810,790
Ensembl chr 2:72,766,771...72,810,790
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases degradation |
ISO |
ATG5 mutant form inhibits the reaction [Camptothecin results in increased degradation of SQSTM1 protein]; Camptothecin inhibits the reaction [Cannabidiol results in increased expression of SQSTM1 mRNA] |
CTD |
PMID:22927544 PMID:34302491 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srgap3 |
SLIT-ROBO Rho GTPase activating protein 3 |
decreases expression |
ISO |
Camptothecin results in decreased expression of SRGAP3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:112,694,932...112,924,466
Ensembl chr 6:112,694,932...112,924,227
|
|
G |
Srxn1 |
sulfiredoxin 1 homolog (S. cerevisiae) |
increases expression |
EXP |
Camptothecin results in increased expression of SRXN1 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 2:151,946,738...151,953,296
Ensembl chr 2:151,947,436...151,953,296
|
|
G |
Stambpl1 |
STAM binding protein like 1 |
increases methylation |
ISO |
Camptothecin results in increased methylation of STAMBPL1 gene |
CTD |
PMID:30720231 |
|
NCBI chr19:34,169,629...34,217,733
Ensembl chr19:34,169,629...34,217,733
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
decreases response to substance |
ISO |
STYXL1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 5:135,776,074...135,807,277
Ensembl chr 5:135,776,074...135,807,239
|
|
G |
Suv39h1 |
suppressor of variegation 3-9 1 |
increases expression |
ISO |
Camptothecin results in increased expression of SUV39H1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr X:7,927,401...7,940,994
Ensembl chr X:7,927,410...7,940,999
|
|
G |
Tab2 |
TGF-beta activated kinase 1/MAP3K7 binding protein 2 |
decreases response to substance |
ISO |
TAB2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr10:7,781,412...7,832,039
Ensembl chr10:7,781,417...7,831,994
|
|
G |
Tap1 |
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) |
increases expression |
ISO |
Camptothecin results in increased expression of TAP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:34,406,530...34,416,199
Ensembl chr17:34,406,527...34,416,199
|
|
G |
Tax1bp3 |
Tax1 (human T cell leukemia virus type I) binding protein 3 |
increases expression |
ISO |
Camptothecin results in increased expression of TAX1BP3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr11:73,067,909...73,072,872
Ensembl chr11:73,067,909...73,073,988
|
|
G |
Tbc1d16 |
TBC1 domain family, member 16 |
decreases expression |
ISO |
Camptothecin results in decreased expression of TBC1D16 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:119,033,869...119,119,354
Ensembl chr11:119,033,871...119,119,325
|
|
G |
Tdp1 |
tyrosyl-DNA phosphodiesterase 1 |
multiple interactions |
ISO |
TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr12:99,850,767...99,921,482
Ensembl chr12:99,850,776...99,921,478
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of TERT protein]; Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TERT protein]; Camptothecin results in increased expression of and results in increased phosphorylation of TERT protein; Glutathione inhibits the reaction [Camptothecin results in increased expression of TERT protein]; NFE2L2 protein affects the reaction [Camptothecin results in increased expression of TERT mRNA]; TERT protein affects the reaction [Camptothecin results in increased expression of MYC protein]; TERT protein affects the reaction [Camptothecin results in increased expression of SP1 protein]; Wortmannin inhibits the reaction [Camptothecin results in increased phosphorylation of TERT protein] |
CTD |
PMID:30851366 |
|
NCBI chr13:73,775,030...73,797,962
Ensembl chr13:73,775,030...73,797,962
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression decreases secretion multiple interactions |
ISO |
Camptothecin results in decreased expression of THBS1 mRNA Camptothecin results in decreased secretion of THBS1 protein THBS1 protein inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] |
CTD |
PMID:16962673 |
|
NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr11:98,631,539...98,659,832
Ensembl chr11:98,631,464...98,659,832
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr14:4,429,599...4,810,538
Ensembl chr14:4,431,611...4,809,435
|
|
G |
Tmem250 |
transmembrane protein 250 |
increases expression |
ISO |
Camptothecin results in increased expression of TMEM250 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:26,026,819...26,030,518
Ensembl chr 2:26,026,826...26,030,533
|
|
G |
Tnfsf9 |
tumor necrosis factor (ligand) superfamily, member 9 |
increases expression |
ISO |
Camptothecin results in increased expression of TNFSF9 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:57,412,113...57,414,757
Ensembl chr17:57,412,325...57,414,757
|
|
G |
Top1 |
topoisomerase (DNA) I |
multiple interactions decreases response to substance decreases activity |
ISO |
[Ciprofloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein; [moxifloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein TOP1 protein mutant form results in decreased susceptibility to Camptothecin Camptothecin analog results in decreased activity of TOP1 protein; Camptothecin results in decreased activity of TOP1 protein |
CTD |
PMID:12097280 PMID:18191106 PMID:20600288 PMID:21056033 PMID:21227924 PMID:23376119 PMID:34635930 More...
|
|
NCBI chr 2:160,487,901...160,564,684
Ensembl chr 2:160,487,808...160,564,684
|
|
G |
Traf6 |
TNF receptor-associated factor 6 |
decreases response to substance |
ISO |
TRAF6 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014
|
|
G |
Trim28 |
tripartite motif-containing 28 |
increases expression |
ISO |
Camptothecin results in increased expression of TRIM28 protein modified form |
CTD |
PMID:25977998 |
|
NCBI chr 7:12,758,079...12,764,959
Ensembl chr 7:12,733,041...12,764,962
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions increases glutathionylation increases activity increases phosphorylation increases response to substance increases expression decreases acetylation affects response to substance decreases response to substance |
ISO EXP |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased expression of TP53 protein]; [SIRT1 mutant form co-treated with Camptothecin] results in increased acetylation of TP53 protein; Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form]; Camptothecin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased acetylation of TP53 protein]; Camptothecin results in increased stability of and results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein; nutlin 3 inhibits the reaction [Camptothecin results in increased expression of TP53 protein]; S-ethyl glutathione inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] Camptothecin results in increased glutathionylation of TP53 protein Camptothecin results in increased activity of TP53 protein Camptothecin results in increased phosphorylation of TP53 protein Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]]; pifithrin inhibits the reaction [Camptothecin results in increased activity of TP53 protein] TP53 protein results in increased susceptibility to Camptothecin Camptothecin results in decreased acetylation of TP53 protein TRP53 protein affects the susceptibility to Camptothecin TP53 mutant form results in decreased susceptibility to Camptothecin; TP53 protein mutant form results in decreased susceptibility to Camptothecin; TP53 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:9673414 PMID:10692111 PMID:11279278 PMID:11741290 PMID:12082016 PMID:13679428 PMID:17555331 PMID:19481069 PMID:20477944 PMID:20978201 PMID:23285096 PMID:24726431 PMID:25269479 PMID:26657896 More...
|
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Trp63 |
transformation related protein 63 |
decreases expression |
ISO |
Camptothecin results in decreased expression of TP63 protein alternative form |
CTD |
PMID:23376119 |
|
NCBI chr16:25,502,513...25,710,842
Ensembl chr16:25,502,513...25,710,852
|
|
G |
Tsg101 |
tumor susceptibility gene 101 |
decreases response to substance |
ISO |
TSG101 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:46,538,693...46,569,716
Ensembl chr 7:46,538,697...46,569,717
|
|
G |
Tulp4 |
TUB like protein 4 |
decreases expression |
ISO |
Camptothecin results in decreased expression of TULP4 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr17:6,156,528...6,290,912
Ensembl chr17:6,156,712...6,301,403
|
|
G |
Twf1 |
twinfilin actin binding protein 1 |
decreases response to substance |
ISO |
TWF1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr15:94,475,829...94,487,727
Ensembl chr15:94,475,832...94,487,770
|
|
G |
Tyms |
thymidylate synthase |
increases expression |
ISO |
Camptothecin results in increased expression of TYMS mRNA |
CTD |
PMID:16568373 |
|
NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615
|
|
G |
Ugt1a6b |
UDP glucuronosyltransferase 1 family, polypeptide A6B |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of UGT1A6 gene |
CTD |
PMID:30720231 |
|
NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725
|
|
G |
Upf1 |
UPF1 RNA helicase and ATPase |
decreases response to substance |
ISO |
UPF1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 8:70,784,143...70,806,418
Ensembl chr 8:70,784,175...70,805,928
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 (isopeptidase T) |
decreases response to substance |
ISO |
USP5 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 6:124,791,982...124,806,404
Ensembl chr 6:124,791,982...124,806,447
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression decreases response to substance |
ISO |
Camptothecin results in decreased expression of VEGFA protein VEGFA protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16356833 PMID:20116850 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions decreases response to substance |
ISO EXP |
[Butyrates co-treated with Camptothecin] results in decreased expression of XIAP protein; [Camptothecin co-treated with FAS protein] results in decreased expression of XIAP protein XIAP protein results in decreased susceptibility to Camptothecin Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein] |
CTD |
PMID:16061681 PMID:16211302 PMID:19633536 PMID:25449198 |
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
G |
Xrcc1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
affects response to substance multiple interactions |
ISO |
XRCC1 protein affects the susceptibility to Camptothecin [XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the susceptibility to Camptothecin] |
CTD |
PMID:35778544 |
|
NCBI chr 7:24,246,124...24,272,863
Ensembl chr 7:24,245,714...24,272,865
|
|
G |
Xrcc3 |
X-ray repair complementing defective repair in Chinese hamster cells 3 |
decreases expression |
ISO |
Camptothecin results in decreased expression of XRCC3 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr12:111,769,626...111,780,326
Ensembl chr12:111,769,626...111,780,307
|
|
G |
Xrcc4 |
X-ray repair complementing defective repair in Chinese hamster cells 4 |
decreases response to substance increases methylation |
ISO |
XRCC4 results in decreased susceptibility to Camptothecin Camptothecin results in increased methylation of XRCC4 gene |
CTD |
PMID:21785230 PMID:30720231 |
|
NCBI chr13:89,997,033...90,237,727
Ensembl chr13:89,922,146...90,237,727
|
|
G |
Yars2 |
tyrosyl-tRNA synthetase 2 (mitochondrial) |
increases expression |
ISO |
Camptothecin results in increased expression of YARS2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr16:16,120,829...16,127,504
Ensembl chr16:16,120,829...16,127,504
|
|
G |
Zap70 |
zeta-chain (TCR) associated protein kinase |
decreases response to substance |
ISO |
ZAP70 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:36,800,912...36,821,899
Ensembl chr 1:36,800,879...36,821,899
|
|
G |
Zc3hc1 |
zinc finger, C3HC type 1 |
decreases response to substance |
ISO |
ZC3HC1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 6:30,366,383...30,391,019
Ensembl chr 6:30,366,379...30,391,027
|
|
G |
Zfp282 |
zinc finger protein 282 |
increases expression |
ISO |
Camptothecin results in increased expression of ZNF282 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:47,853,433...47,885,419
Ensembl chr 6:47,854,138...47,885,419
|
|
G |
Zfp383 |
zinc finger protein 383 |
increases expression |
ISO |
Camptothecin results in increased expression of ZNF383 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 7:29,607,705...29,616,238
Ensembl chr 7:29,607,648...29,616,238
|
|